Policymakers should consider the potential for replacing the phthalate DEHP in medical devices but must weigh up its usefulness in treatment and the drawbacks of alternative substances, experts have advised the European Commission.
The Scientific Committee on Emerging and Newly-Identified Health Risks said that premature babies “represent a high-risk population to DEHP exposure”, while patients undergoing haemodialysis may receive more than the tolerable daily intake (TDI) and “are at risk of DEHP-induced effects”.
Please enter your details
Not a subscriber?
Take a free trial now to discover the critical insights and updates our coverage offers subscribers.